Related Experiment Videos
MEK1 and Erk1/2 kinases as targets for the modulation of radiation responses
C Belka1, P Knippers, J Rudner
1Department of Radiotherapy, University of Tuebingen, Germany. claus.belka@uni-tuebingen.de
Background:
The activation of mitogenic cascades via Ras, c-Raf-1, MEK-1, Erk1/2 is a hall- mark of oncogenic transformation. The cascade is also anti-apoptotic by modulation of Bcl-2, Bcl-xL and BAD function. The impact of MEK-1 on radiation resistance and the role of drugs targeting MEK-1 for the modulation of resistance is unclear.
Materials And Methods:
Activation of MEK-1 in four carcinoma cell lines was analyzed using Erk1/2 phosphospecific antibodies. MEK-1 was blocked by PD98059 (2-amino-3methoxyflavin) and influence on radiation responses was determined by apoptotic morphology, caspase-3 activation and colony formation assays.
Results:
MEK-1 kinase was constitutively active and inhibitable by PD98059. The low radiation induced apoptosis rate was not increased by MEK inhibition. PD98059 did not influence cell growth and radiation induced clonogenic cell death.
Conclusion:
Since PD98059 did not alter radiation responses despite blocking MEK-1 kinase, MEK-1 and Erk1/2 are not involved in radiation resistance. Thus PD98059 has no potential in the modulation of radiation responses.
Insights
MEK-1 inhibition does not affect cancer cell radiation resistance. Blocking MEK-1 (MAPK/ERK kinase 1) with PD98059 did not alter apoptosis or clonogenic cell death, indicating no role in radiation resistance.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- The Ras-Raf-MEK-ERK pathway is crucial for cell growth and survival.
- This pathway's role in cancer radiation resistance remains unclear.
- MEK-1 (MAPK/ERK kinase 1) is a key component of this mitogenic cascade.
Purpose of the Study:
- To investigate the role of MEK-1 in cancer cell radiation resistance.
- To determine if MEK-1 inhibition can modulate radiation responses.
- To evaluate the potential of MEK-1 inhibitors like PD98059 in cancer therapy.
Main Methods:
- Analyzed MEK-1 activation in four carcinoma cell lines.
- Inhibited MEK-1 using PD98059 (2-amino-3-methoxyflavin).
- Assessed radiation response through apoptosis assays, caspase-3 activation, and colony formation assays.
Main Results:
- MEK-1 kinase was constitutively active and successfully inhibited by PD98059.
- MEK-1 inhibition did not increase the rate of radiation-induced apoptosis.
- PD98059 did not affect cell growth or radiation-induced clonogenic cell death.
Conclusions:
- MEK-1 and ERK1/2 are not involved in cancer cell radiation resistance.
- The MEK-1 inhibitor PD98059 has no potential for modulating radiation responses.
- Targeting MEK-1 is unlikely to enhance the efficacy of radiation therapy.